Advances in type 2-high asthma therapy: what remains missing?

Area of Science:

• Immunology
• Pharmacology
• Health Economics

Background:

• Type 2-high asthma (T2HA) is a severe inflammatory condition.
• Current biologics offer limited solutions for many patients, who remain symptomatic or corticosteroid-dependent.
• High costs create access barriers to advanced T2HA therapies.

Purpose of the Study:

• To synthesize evidence on current and emerging T2HA interventions.
• To evaluate limitations in late-stage drug development, biologic durability, and small-molecule progress.
• To identify cost-access barriers and explore future therapeutic and economic strategies.

Main Methods:

• Comprehensive literature search across multiple databases (PubMed, Embase, Web of Science, Scopus, Cochrane Library, EconLit, ClinicalTrials.gov, WHO-ICTRP) from January 2005 to June 2025.
• Synthesis of evidence from randomized trials, economic evaluations, and translational studies.
• Analysis focused on biologics, small molecules, cell-based, and microbiome-directed interventions, examining attrition, durability, and cost.

Main Results:

• Phenotype-guided biologics have advanced T2HA treatment but face plateaus in effectiveness and uncertain long-term safety.
• Progress in small-molecule drugs for T2HA is slow, with significant cost-access barriers.
• Ultra-long-acting biologics show potential but require further evaluation for durability and pediatric data.

Conclusions:

• Future T2HA management requires value-based pricing, adaptive clinical trials, and combination therapies.
• Sustainable and equitable T2HA care necessitates integrated scientific, regulatory, and economic approaches.
• Moving beyond narrow cytokine targets is crucial for addressing T2HA comprehensively.